I am an immunologist with a background in virology and peptide chemistry and my work is therefore inter-disciplinary but focused on the design of synthetic, epitope-based vaccines against infectious agents particularly influenza and hepatitis C viruses an
Role Of The Hepatitis C Virus Glycoprotein E2 Variable Regions In Viral Entry And Antibody Mediated Neutralization.
Funder
National Health and Medical Research Council
Funding Amount
$542,462.00
Summary
The first stage of Hepatitis C Virus replication involves attaching to liver cells. This study is aimed at understanding how the virus attaches to liver cells and how antibodies raised during infection, block this interaction. In addition, this study aims to examine how the virus modulates its structure to evade the immne system, allowing the virus to establish chronic infections. The results of this study will guide future vaccine design for HCV.
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$585,269.00
Summary
This Fellowship will allow Professor Lloyd to continue clinical and laboratory research in two areas: firstly, in relation to prevention of transmission of hepatitis C infection, and scale up of antiviral treatments, particularly amongst prisoners. Secondly, in studies investigating the biological basis of chronic fatigue states following acute infection or cancer treatment, and also in development of effective treatment for chronic fatigue states.
I am a molecular virologist researching the host response to hepatitis C virus (HCV) infection with the aim of understanding how the liver clears HCV infection. An understanding of this process will hopefully lead to novel antiviral strategies to combat not only HCV but a broad range of other viral infections.
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$532,630.00
Summary
Professor Lloyd will continue studies of the factors which lead to varied clinical outcomes from common infectious diseases. The outcomes include chronic or persistent illness, rather than prompt recovery. The factors being studied include aspects of the microbes causing the infection; and aspects of the individual suffering from infection, including genetic make-up, immune defences, and treatment responses. The infections studied include common "flu-like" illnesses, as well as hepatitis C.
Reducing The Health, Social And Economic Burden Of Injecting Drug Use In Australia
Funder
National Health and Medical Research Council
Funding Amount
$2,606,037.00
Summary
Injecting drug use (IDU) is a disproportionately large source of health and social harm. This CRE unites Australia’s leading scientists in the IDU field – researchers working on blood-borne virus epidemiology and treatment, overdose prevention, justice health and psychiatric health - and experts from key non-government organisations. The CRE will develop new ways to improve the health of injecting drug users, and reduce the health and social burden of IDU to the Australian community.
UNDERSTANDING HEPATITIS C VIRUS-SPECIFIC T CELL TOLERANCE
Funder
National Health and Medical Research Council
Funding Amount
$429,710.00
Summary
Most individuals who are infected with hepatitis C virus (HCV) develop a persistent infection that is lifelong and are at risk of developing serious liver disease, including liver cancer. The evidence suggests that an inadequate immune response is responsible for the inability of the patient to resolve the infection, but it is not clear which stage of the immunological cascade might be targeted. In this project, we will test the hypothesis that HCV antigen induce supressor T cells This will have ....Most individuals who are infected with hepatitis C virus (HCV) develop a persistent infection that is lifelong and are at risk of developing serious liver disease, including liver cancer. The evidence suggests that an inadequate immune response is responsible for the inability of the patient to resolve the infection, but it is not clear which stage of the immunological cascade might be targeted. In this project, we will test the hypothesis that HCV antigen induce supressor T cells This will have the effect of inhibiting the immune response and result in the outcome that we currently recognise as persistent HCV infection.Read moreRead less
A successful vaccine for RNA viruses like HIV and hepatitis C (HCV) will require cell mediated immunity (CMI) as well as neutralising antibody. The vaccine delivery vehicles which are currently in use to generate CMI are not effective because individuals have pre-existing immunity to the delivery vehicle or generate immunity to the vehicle in a multiple dose regimen. This project is designed to overcome this limitation by using multiple vaccine delivery vehicles which encode common HCV proteins.
Using The Information Inherent In Immune Responses To Design Vaccines
Funder
National Health and Medical Research Council
Funding Amount
$526,571.00
Summary
The parts of viruses, bacteria and of cancer cells that are recognised by the immune system are called epitopes. Epitopes are generated from these agents by dendritic cells which are found in many parts of the body where they act as sentinels on the look out for dangerous organisms. Epitopes are very small pieces of the proteins against which immune responses are mounted and can be readily synthesised in the laboratory. If we were to design vaccines that are made of epitopes such that the immune ....The parts of viruses, bacteria and of cancer cells that are recognised by the immune system are called epitopes. Epitopes are generated from these agents by dendritic cells which are found in many parts of the body where they act as sentinels on the look out for dangerous organisms. Epitopes are very small pieces of the proteins against which immune responses are mounted and can be readily synthesised in the laboratory. If we were to design vaccines that are made of epitopes such that the immune response is focussed to those exact regions of infectious agents it could lead to an immune response that eliminates the agent. The problem is, however, that we usually do not know which part of the virus, bacterium or cancer cell is recognised as an epitope. So the identification of epitopes is a limitation to the design of epitope-based vaccines. Anyone who has encountered a virus, bacterium or tumour cell and who has raised an immune response will have developed antibodies and immune cells able to recognise the right parts of the infectious agent or cancer cell. These antibodies and immune cells now contain information about the epitopes. We will use antibodies and blood cells obtained from people immune to the disease to extract epitopes from a panel of protein fragments that represent the agent against which we wish to make vaccines. These newly discovered epitopes will then be incorporated into totally synthetic vaccines. These vaccines will also incorporate a simple lipid molecule which specifically targets and activates the dendritic cell that is key for the induction of potent immune responses. All of the technologies we propose are in place and we have proof of principle that the approach leads to the successful design of vaccines that are effective against infectious diseases and cancers.Read moreRead less